After the success of 2025, where we raised more than £3000 thanks to generous donations, come join us again for a 5K run or walk to raise awareness of Huntington’s Disease and support the amazing work

BACKGROUND Cognitive impairments are a hallmark of Huntington's disease (HD). METHODS Seventy-one participants (43 HD gene-expanded [HDGE], 28 healthy controls) from the HD-Young Adult Study at tw...

Nature Reviews Neurology - Genome-wide association studies have identified genetic modifiers, mostly DNA repair genes, that significantly influence the onset and progression of Huntington disease,...

We're delighted that Dr Mena Farag (UCL Queen Square Institute of Neurology) was awarded the UK DRI PhD Prize on 9th December 2025 at Connectome 2025.

The football financier who helped the Saudis buy Newcastle United has Huntington’s disease, a hereditary terminal condition with debilitating symptoms. Now a new treatment has been pioneered by a British...

Sarah Tabrizi is part of Nature’s 10, a list of people who shaped science in 2025.

UCL Discovery is UCL's open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.

Professor Sarah Tabrizi, Director of the UCL Huntington’s Disease Centre, has been awarded the British Neuroscience Association (BNA) Outstanding Contribution to Neuroscience Award for 2025, the…

Subscription and open access journals from Sage, the world's leading independent academic publisher.

Professor Sarah Tabrizi, Director of the UCL Huntington’s Disease Centre, has been awarded the British Neuroscience Association (BNA) Outstanding Contribution to Neuroscience Award for 2025, the assoc...

Background Huntington's disease (HD) is characterized by early, selective, progressive vulnerability of striatal medium spiny neurons (MSNs). Proenkephalin (PENK), a precursor of opioid peptides abu...

One of the most devastating diseases finally has a treatment that can slow its progression and transform lives, tearful doctors tell BBC.

Promising blood-based biomarkers of neuropathology have emerged with potential for therapeutic development and disease monitoring. However, these tools will require specialist tertiary services for in...

A series of digital tests, carried out via a smartphone app, could enhance the detection of disease progression in Huntington’s disease and improve the efficiency of clinical trials, finds research le...

Background Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by cognitive, neuropsychiatric and motor symptoms caused by a CAG trinucleotide repeat expansion in the ...

MSH3 lowering by antisense oligonucleotides dose-dependently reduces CAG repeat expansions in iPSC-derived neurons from a patient with HD.

A comprehensive longitudinal analysis of individuals with preclinical Huntington’s disease identifies biomarkers of neurodegeneration and somatic expansion in blood DNA, detectable years before sympto...

A comprehensive longitudinal analysis of individuals with preclinical Huntington’s disease identifies biomarkers of neurodegeneration and somatic expansion in blood DNA, detectable years before sympto...

Subtle changes in the brain, detectable through advanced imaging, blood and spinal fluid analysis, happen approximately twenty years before a clinical motor diagnosis in people with Huntington’s disea...